Glaxo Launches Phase 3 Study Into Eltrombopag Effect on MDS Sufferers
25 June 2014 - 8:45PM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) Wednesday said it began a
late-stage study to evaluate the effectiveness of Eltrombopag--a
drug marketed as Promacta in the U.S. and Revolade in Europe--on
people with myelodysplastic syndromes, or MDS, a type of cancer in
which the bone marrow doesn't make enough healthy blood cells.
The "phase three" study will examine the drug's effectiveness in
boosting platelet production in combination with azacitidine, an
existing medicine, GSK said.
Shares at 0840 GMT down 13 pence or 0.8% at 1,564 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024